TABLE 1.
Mean pharmacokinetic parameter estimates following administration of single oral doses of abacavir, ZDV, and 3TC alone or in combination to HIV-infected subjectsa
| Drug (dose [mg]) | Treatment | AUC0–∞ (μg · h/ml) | Cmax (μg/ml) | Tmax (h) | t1/2 (h) |
|---|---|---|---|---|---|
| Abacavir (600) | Abacavir | 11.3 (30) | 4.24 (28) | 1.29 (32) | 1.50 (24) |
| Abacavir + ZDV | 11.7 (29) | 4.49 (30) | 1.35 (40) | 1.47 (23) | |
| Abacavir + 3TC | 11.5 (28) | 4.33 (30) | 1.41 (23) | 1.50 (18) | |
| Abacavir + ZDV + 3TC | 12.2 (33) | 4.56 (37) | 1.39 (33) | 1.50 (22) | |
| ZDV (300) | ZDV | 2.01 (40) | 1.64 (46) | 0.52 (24) | 1.43 (23) |
| ZDV + abacavir | 2.21 (25) | 1.30 (37) | 0.90 (37) | 1.30 (20) | |
| ZDV + 3TC | 1.89 (35) | 1.57 (44) | 0.62 (48) | 1.32 (15) | |
| ZDV + abacavir + 3TC | 2.22 (35) | 1.28 (45) | 1.00 (39) | 1.35 (17) | |
| GZDV | ZDV | 12.2 (26) | 9.41 (24) | 0.71 (20) | 1.40 (19) |
| ZDV + abacavir | 17.3 (32) | 9.21 (39) | 1.31 (32) | 1.31 (20) | |
| ZDV + 3TC | 11.9 (22) | 9.26 (33) | 0.85 (41) | 1.41 (24) | |
| ZDV + abacavir + 3TC | 16.2 (27) | 8.64 (34) | 1.21 (29) | 1.26 (17) | |
| 3TC (150) | 3TC | 5.31 (30) | 1.50 (36) | 0.88 (38) | 3.27 (16) |
| 3TC + abacavir | 4.49 (32) | 0.97 (34) | 1.81 (21) | 3.54 (15) | |
| 3TC + ZDV | 5.23 (26) | 1.37 (34) | 0.87 (42) | 3.20 (12) | |
| 3TC + abacavir + ZDV | 4.79 (42) | 0.97 (42) | 1.60 (40) | 3.58 (22) |
a
n = 13 for all drug doses. Values in parentheses are percent coefficients of variation.